Medifast Appoints Nicholas Johnson as CEO, Authorizes 250,000 New Shares for Incentive Plan
MED sits 42% above its 52-week low of $9.22.
Summary
Medifast finalized its CEO transition, appointing Nicholas Johnson and approving a significant increase in shares for its employee incentive plan.
Key Events · Executive and Board Changes · MED
-
CEO Appointment Finalized
Nicholas Johnson was officially appointed Chief Executive Officer, effective June 1, 2026, succeeding Daniel Chard, who transitions to non-executive Chairman. This leadership change was previously announced in an 8-K filing on January 5, 2026.
-
New CEO Compensation Details
Nicholas Johnson's new compensation package includes an annual base salary of $600,000, a target bonus of 100% of his base salary, and a Long Term Incentive target of 250% of his base salary, representing a 69% increase in total target compensation from his prior role.
-
Share Incentive Plan Approved
Stockholders approved an amendment to the 2012 Share Incentive Plan, increasing the number of shares authorized for issuance by 250,000 shares. These shares are intended for equity compensation for executive officers and other key individuals.
-
Routine Shareholder Votes
Stockholders elected all nominated directors, ratified RSM US LLP as the independent registered public accounting firm for 2026, and approved executive compensation on an advisory basis.
Analysis · MED · Manufacturing
This 8-K confirms the finalization of a previously announced leadership transition, with Nicholas Johnson officially taking over as CEO on June 1, 2026, and Daniel Chard moving to non-executive Chairman. The filing details Johnson's new compensation package, which includes a 69% increase in total target compensation. In the context of recent significant revenue declines and net losses reported in Q1 2026, the approval by stockholders to increase authorized shares for the 2012 Share Incentive Plan by 250,000 shares is notable. While this authorization for future equity compensation could lead to potential dilution, it is a standard mechanism to attract and retain key talent, which is crucial during challenging periods for the company.
At the time of this filing, MED was trading at $13.09 on NYSE in the Manufacturing sector, with a market capitalization of approximately $145.5M. The 52-week trading range was $9.22 to $15.46. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.